Glycoprotein Analysis for the Diagnostic Evaluation of Platelet Disorders

ABSTRACT

Platelet glycoproteins subserve a wide variety of critical functions in blood platelets. Congenital deficiencies or functional abnormalities in platelet glycoproteins may produce serious bleeding disorders such as Glanzmann thrombasthenia or Bernard-Soulier syndrome. Other hematologic disorders, such as Fanconi anemia and various myelodysplastic syndromes, may also be associated with abnormalities in platelet glycoproteins. Additionally, several acquired disorders involving the major platelet glycoproteins are increasingly being recognized. The large number of techniques, now available to characterize platelet glycoprotein disorders, reflect the many advances in biochemistry, molecular analysis, flow cytometry, and, most recently, proteomics. The application of platelet glycoprotein analysis to a wide range of clinical disorders is reviewed in this article.

KEYWORDS

Platelets - platelet glycoproteins - platelet membrane disorders

REFERENCES

• 1 Nurden A T, Nurden P. Inherited disorders of platelets: an update.  Curr Opin Hematol. 2006;  13 157-162
• 2 Coller B S, Shattil S J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.  Blood. 2008;  112 3011-3025
• 3 Caen J P, Nurden A T, Jeanneau C et al.. Bernard-Soulier syndrome. A new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein.  J Lab Clin Med. 1976;  87 586-596
• 4 Nurden A T, Caen J P. Specific roles for platelet surface glycoproteins in platelet function.  Nature. 1975;  255 720-722
• 5 Phillips D R, Agin P P. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins.  J Clin Invest. 1977;  60 535-545
• 6 Bennett J S, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine.  J Clin Invest. 1979;  64 1393-1401
• 7 Mustard J F, Packham M A, Kinlough-Rathbone R L, Perry D W, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation.  Blood. 1978;  52 453-466
• 8 McGregor J L, Clezardin P, James E, McGregor L, Dechavanne M, Clemetson K J. Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment.  Eur J Biochem. 1985;  148 97-106
• 9 Handa M, Titani K, Holland L Z, Roberts J R, Ruggeri Z M. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments.  J Biol Chem. 1986;  261 12579-12585
• 10 Ward C M, Andrews R K, Smith A I, Berndt M C. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.  Biochemistry. 1996;  35 4929-4938
• 11 Kunicki T J, Nurden A T, Pidard D, Russell N R, Caen J P. Characterization of human platelet glycoprotein antigens giving rise to individual immunoprecipitates in crossed-immunoelectrophoresis.  Blood. 1981;  58 1190-1197
• 12 Karpatkin S, Shulman S, Howard L. Crossed immunoelectrophoresis of human platelet membranes.  Methods Enzymol. 1992;  215 440-455
• 13 Fabris F, Cordiano I, Mazzuccato M, Pradella P, Randi M LG. Labeling of platelet surface glycoproteins with biotin derivatives.  Thromb Res. 1992;  66 409-419
• 14 Gibbins J M. Techniques for analysis of proteins by SDS-polyacrylamide gel electrophoresis and Western blotting.  Methods Mol Biol. 2004;  273 139-152
• 15 Michelson A D. Evaluation of platelet function by flow cytometry.  Pathophysiol Haemost Thromb. 2006;  35 67-82
• 16 Michelson A D, Linden M D, Barnard M R, Furman M I, Frelinger III A L. Flow cytometry. In: Michelson AD Platelets. 2nd ed. New York, NY; Elsevier 2007: 545-564
• 17 Rand M L, Leung R, Packham M A. Platelet function assays.  Transfus Apher Sci. 2003;  28 307-317
• 18 Enjeti A K, Lincz L F, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology.  Semin Thromb Hemost. 2007;  33 771-779
• 19 Israels S. Diagnostic evaluation of platelet function disorders in neonates and children: an update.  Semin Thromb Hemost. 2009;  35 181-188
• 20 Althaus K, Greinacher A. MYH9-related platelet disorders.  Semin Thromb Hemost. 2009;  35 189-203
• 21 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.  Semin Thromb Hemost. 2009;  35 158-167
• 22 McGlasson D, Fritsma G. Whole blood platelet aggregometry and platelet function testing.  Semin Thromb Hemost. 2009;  35 168-180
• 23 Nurden A, Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders.  Semin Thromb Hemost. 2009;  35 204-212
• 24 Weiss H. Impaired platelet procoagulant mechanisms in patients with bleeding disorders.  Semin Thromb Hemost. 2009;  35 233-241
• 25 Glanzmann Thombasthenia Database .Mount Sinai School of Medicine, Department of Medicine. 2008 Available at: http://www.sinaicentral.mssm.edu/intranet/research/glanzmann Accessed January 28, 2009
• 26 Kiyoi T, Tomiyama Y, Honda S et al.. A naturally occurring Tyr143His alpha IIb mutation abolishes alpha IIb beta 3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects.  Blood. 2003;  101 3485-3491
• 27 Goodall A H, Appleby J. Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation.  Methods Mol Biol. 2004;  272 225-253
• 28 Shattil S J, Cunningham M, Hoxie J A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry.  Blood. 1987;  70 307-315
• 29 Lanza F, Stierle A, Fournier D et al.. A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg–214Trp mutation.  J Clin Invest. 1992;  89 1995-2004
• 30 Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient.  Vox Sang. 1988;  55 109-113
• 31 Male C, Koren D, Eichelberger B, Kaufmann K, Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography.  Vox Sang. 2006;  91 174-177
• 32 Giannini S, Mezzasoma A M, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry.  Cytometry B Clin Cytom. 2008;  74 194-199
• 33 Vijapurkar M, Ghosh K, Shetty S, McLane M A, Moura da Silva A M, Butera D. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia.  Haematologica. 2008;  93 797-798
• 34 Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome.  Blood. 2002;  100 2102-2107
• 35 Miller J L, Lyle V A, Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease.  Blood. 1992;  79 439-446
• 36 Vettore S, Scandellari R, Moro S et al.. Novel point mutation in a leucine-rich repeat of the GPIbalpha chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant.  Haematologica. 2008;  93 1743-1747
• 37 Giannini S, Mezzasoma A M, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.  Haematologica. 2007;  92 1647-1654
• 38 Kunicki T J, Johnson M M, Aster R H. Absence of the platelet receptor for drug-dependent antibodies in the Bernard-Soulier syndrome.  J Clin Invest. 1978;  62 716-719
• 39 Visentin G P, Wolfmeyer K, Newman P J, Aster R H. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry.  Transfusion. 1990;  30 694-700
• 40 van den Bemt P M, Meyboom R H, Egberts A C. Drug-induced immune thrombocytopenia.  Drug Saf. 2004;  27 1243-1252
• 41 Nurden A T, Nurden P, Bermejo E, Combrie R, McVicar D W, Washington A V. Phenotypic heterogeneity in the gray platelet syndrome extends to the expression of TREM family member, TLT-1.  Thromb Haemost. 2008;  100 45-51
• 42 Drouin A, Favier R, Masse J M et al.. Newly recognized cellular abnormalities in the gray platelet syndrome.  Blood. 2001;  98 1382-1391
• 43 Diamandis M, Paterson A D, Rommens J M et al.. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.  Blood. 2008;  , November 6 (Epub ahead of print)
• 44 Diamandis M, Veljkovic D K, Maurer-Spurej E, Rivard G E, Hayward C P. Quebec platelet disorder: features, pathogenesis and treatment.  Blood Coagul Fibrinolysis. 2008;  19 109-119
• 45 Noris P, Guidetti G F, Conti V et al.. Autosomal dominant thrombocytopenias with reduced expression of glycoprotein Ia.  Thromb Haemost. 2006;  95 483-489
• 46 Arthur J F, Dunkley S, Andrews R K. Platelet glycoprotein VI-related clinical defects.  Br J Haematol. 2007;  139 363-372
• 47 Dunkley S, Arthur J F, Evans S, Gardiner E E, Shen Y, Andrews R K. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway.  Br J Haematol. 2007;  137 569-577
• 48 Holzhauer S, Sitaru A G, Ebell W et al.. Decreased platelet reactivity identified by whole blood flow cytometry in Fanconi anaemia patients.  Thromb Haemost. 2007;  98 1291-1297
• 49 Swerdlow S H, Campo E, Harris N L et al.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France; International Agency for Research on Cancer 2008
• 50 Seidl C, Siehl J, Ganser A et al.. Platelet glycoprotein expression in patients with myelodysplastic syndrome.  Thromb Res. 2000;  100 27-34
• 51 Izumi M, Takeshita A, Shinjo K et al.. Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence.  Eur J Haematol. 2001;  66 245-252
• 52 Senzel L, Gnatenko D V, Bahou W F. Genomic and proteomic applications in diagnosis of platelet disorders and classification.  Semin Thromb Hemost. 2008;  34 532-538
• 53 Curtis B R. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders.  Semin Thromb Hemost. 2008;  34 539-548
• 54 Garcia B A, Smalley D M, Cho H, Shabanowitz J, Ley K, Hunt D F. The platelet microparticle proteome.  J Proteome Res. 2005;  4 1516-1521
• 55 Maynard D M, Heijnen H F, Horne M K, White J G, Gahl W A. Proteomic analysis of platelet alpha-granules using mass spectrometry.  J Thromb Haemost. 2007;  5 1945-1955
• 56 Maurer-Spurej E, Kahr W H, Carter C J, Pittendreigh C, Cameron M, Cyr T D. The value of proteomics for the diagnosis of a platelet-related bleeding disorder.  Platelets. 2008;  19 342-351